Theravance/Glaxo spin-off happens next quarter

Part of Theravance (THRX) will separate from partner GlaxoSmithKline (GSK) next quarter.

Theravance Biopharma, the new firm, will retain the rights to Relvar, Breo and Anoro Ellipta drugs, with combined peak sales estimates of $3.5B.

The company will launch with $300M in capital, one FDA-approved product Vibativ, an injectable antibiotic and three Phase 2 product candidates.

Glaxo retains 85% rights to the three Theravance pipeline prospects.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs